SynapDx Corporation Raises $9 Million in Series A Funding
Company to Develop Proprietary Technologies for the Early Detection of Autism
WALTHAM, Mass., June 1 /PRNewswire/ -- SynapDx Corp., a new company focused on developing and commercializing diagnostic testing for the early detection of autism, announced the completion of a $9 million Series A financing by Bain Capital Ventures, General Catalyst Partners, and North Bridge Venture Partners.
"Autism has a profound effect on children and their families," said Stanley N. Lapidus, the company's founder, President and Chief Executive Officer. "The right objective blood-based diagnostic test for autism may help achieve earlier diagnosis, more rapid intervention, and improved outcomes."
About SynapDx Corp.
SynapDx was formed to develop and commercialize blood-based diagnostic tests for the early detection of autism. SynapDx was founded by Stanley N. Lapidus, an experienced life-sciences entrepreneur and inventor with 31 issued patents. Mr. Lapidus founded and led Cytyc Corp., EXACT Sciences Corp., and Helicos BioSciences Corp. Mr. Lapidus' co-founders of SynapDx Corp. include Jeffrey R. Luber, Esq. and Patrick A. Anquetil, PhD.
SOURCE SynapDx Corp.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.